Clinical efficacy of cisplatin combined recombinant human adenovirus type 5 intraperitoneal perfusion in the treatment of gastric cancer complicated with malignant ascites
Objective To explore the clinical efficacy of cisplatin combined recombinant human adenovirus type 5(H101)intraperitoneal perfusion in the treatment of gastric cancer complicated with malignant ascites.Method A total of 68 patients with gastric cancer complicated with malignant ascites were divided into cisplatin group(n=34,received cisplatin intraperitoneal perfusion)and cisplatin combined with H101 group(n=34,received cisplatin combined H101 in-traperitoneal perfusion)by random number table method.The response of ascites,interval of ascites,survival,quality of life and adverse reactions were compared between the two groups.Result The overall response rate of ascites in cisplat-in combined with H101 group was 73.5%,which was higher than 50.0%in cisplatin group,and the difference was statisti-cally significant(P<0.05).The interval of ascites in cisplatin combined with H101 group was(34.02±9.79)days,which was significantly longer than(27.56±9.36)days in cisplatin group,and the difference was statistically significant(P<0.01).The median overall survival in cisplatin combined with H101 group was longer than that in cisplatin group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Cisplatin combined H101 peritoneal perfusion in the treatment of patients with gastric cancer complicated with malignant ascites can safely and effectively control the generation of ascites,improve the quality of life and prolong the survival of patients.
gastric cancermalignant ascitesrecombinant human adenovirus type 5cisplatinclinical efficacy
NETL
NSTL
万方数据
